Literature DB >> 23590816

Therapies for obesity and medication-associated weight gain.

Robert H Howland1.   

Abstract

Compared to the general population, individuals with psychiatric illness, especially serious and chronic mood and psychotic disorders, are more likely to be overweight or obese, have higher rates of weight-related medical conditions, and have greater non-suicide mortality rates. Lorcaserin (Belviq(®)), phentermine/topiramate combination (Qsymia(®)), and bupropion/naltrexone combination have been demonstrated to be effective for the treatment of obesity, as an adjunct to a reduced-calorie diet and physical activity, although their absolute safety has yet to be established with more widespread use or longer use. Bariatric surgery is an effective approach for morbid obesity, but careful psychiatric assessment before and follow up after surgery is necessary. Behavioral lifestyle interventions to promote weight loss are effective and should be implemented along with or instead of drug therapies or surgery. Copyright 2013, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23590816     DOI: 10.3928/02793695-20130411-01

Source DB:  PubMed          Journal:  J Psychosoc Nurs Ment Health Serv        ISSN: 0279-3695            Impact factor:   1.098


  2 in total

1.  The Mitigating Effect of Phentermine and Topiramate on Weight Regain After Roux-en-Y Gastric Bypass Surgery.

Authors:  Nawfal W Istfan; Wendy A Anderson; Donald T Hess; Liqun Yu; Brian Carmine; Caroline M Apovian
Journal:  Obesity (Silver Spring)       Date:  2020-06       Impact factor: 5.002

Review 2.  Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date.

Authors:  Assumpta Caixàs; Lara Albert; Ismael Capel; Mercedes Rigla
Journal:  Drug Des Devel Ther       Date:  2014-09-18       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.